Eisai expands in South Africa, filing for approval of Halaven and Fycompa
Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the filing of its two products - Halaven (eribulin) for metastatic breast cancer and Fycompa (perampanel) for epilepsy - to The Medicines Control Council (MCC).
The South African government has set out plans to introduce a universal health care system with the public health budget growing considerably. The South African pharmaceutical market is also expected to double in the next six years. Eisai's continued growth is part of the company's Hayabusa plan to have a presence in the top 20 pharmaceutical markets and deliver effective treatments to more than 500 million patients by 2015, the drugmaker said.
SA market set to grow to $4.2 billion by 2020
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze